{"name":"NBE-Therapeutics AG","slug":"nbe-therapeutics-ag","ticker":"","exchange":"","domain":"","description":"NBE-Therapeutics AG is a biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. The company's lead candidate, NBE-002, has been discontinued, and they continue to explore new opportunities in oncology.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxOamt0S2VkT2M0NkdBNzZUdDRZZGoySzZDM2hhZ2ZxZ0wtd1RVaVJPOXByclV4VmZScDMtMERuczdib0hkNFhtcjZiNlZCM1FuWFV4SEdZSjRLV1NENFRxb2J3UjlmZC1zanREZWJvNm5GMFFOcC1FY2Ewb01qMk1qeXlDZVdRNFN5TGJYclpPVS0tV1htZl8xdVlqbkc4dG9sWHlFczRqa2pBT3NaZEZJVmhhMVh3T1JBdEN5Z3NSb2ZPanAweFlxT01HY3ZwTUxKTU9SaWJuR2lnNVE4WVN0QmlyWTFkLWl1V2pqQzB2ZzNQMW9vSktUaHR0cUhZcHlLRkdCd2ZnOTNidldvTk56R2c2VWduaWdvU2FEYVo5Y1ZYel93N2c?oc=5","date":"2026-03-26","type":"pipeline","source":"Barchart.com","summary":"Metastatic Triple-Negative Breast Cancer Market: Strong Growth Potential Across APAC Through 2036, Driven by Innovation and Rising Disease Burden | DelveInsight - Barchart.com","headline":"Metastatic Triple-Negative Breast Cancer Market: Strong Growth Potential Across APAC Through 2036, Driven by Innovation ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQOVNGUThyNjkyenVkNDkzeEVtTHRLN1JlUUJGRmpTNnQybEZTSDdlOFpIRThzbjJuVy1td1BMNThqWkVCbFJiSC1QVW1rQWU1czE4dFZqQmt2SzhvZUdLNXd3RURFOEk5UFpaSVJLSER1ZFV1dVl5SVc3QVBQUlMwdS1JcmZBcUZtYkg4WGNGWjM1Mlh3b19xLWEyZnU?oc=5","date":"2025-04-04","type":"pipeline","source":"Switzerland Global Enterprise (S-GE)","summary":"NBE Therapeutics opens new location in Basel - Switzerland Global Enterprise (S-GE)","headline":"NBE Therapeutics opens new location in Basel - Switzerland Global Enterprise (S-GE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQSG44N2x5M25hQTFnTmZqbnpNZGtFT0dwb2ZmN05FRDZQaVJSanI0SloxNHhaXzE3R3QxM1lmRTdWbXRRSXl2OEZ4VjByN3M2aFlkR3duV0lIdzlpbjYydjJkMDJwSk9OUXJvNGhkcW1nNFBHNXNsSzhvRW1NcVNOQnZpeDlpWU12TnozU0RiMEJ2LURGQS04OWRZU28xNkc4LUF3dkU4YkpfY3BWYVlmQzBqdmF3R3A5Q003MUxjZXpyR3JUaDBuaVVpV0poeEU?oc=5","date":"2025-04-03","type":"pipeline","source":"boehringer-ingelheim.com","summary":"New NBE Therapeutics antibody-drug conjugate R&D center - boehringer-ingelheim.com","headline":"New NBE Therapeutics antibody-drug conjugate R&D center - boehringer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNODVjTUhXRXY4VkdTdEVlQWtsTUp6aTRwTkwwNkpDNnB5ZWdza1VyUzh6b21CWDIyQ0FRU1JfNllhdHR4YU4tNXk1SkpXaGRkdVZncE1rZnNFellIWk1SU3llUW9RNXVFdjkyLVkxSldWblVVMm54d0FwVmRiSDhjTzg0cEF1aGt6ZjlLb2hEQnRnYkxzOGpYNVNMQTd3TXg5V2pR?oc=5","date":"2025-02-20","type":"deal","source":"BioWorld News","summary":"Radiance wins ROR1 ADC rights from CSPC in potential $1B+ deal - BioWorld News","headline":"Radiance wins ROR1 ADC rights from CSPC in potential $1B+ deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSUZqS3RMSmZTYXZZZTZfYWtZWExrOFNJSnFyaEZhRmplaHdaUjVCQkhka0NLRUhLMXJHZHJDQ1VVb3hkQXZRNmJudTRCUDdBbElkTldoTTgyanpiZ1FSSFdiUHBUWWFnUy1HUHFYVWx5VW94U2VoWVp3cEJreWpITWdmeVdrUHhYY1U2enh3RmM?oc=5","date":"2025-01-01","type":"pipeline","source":"Switzerland Global Enterprise (S-GE)","summary":"Clear Solutions Labs seeks to benefit from the Basel Area - Switzerland Global Enterprise (S-GE)","headline":"Clear Solutions Labs seeks to benefit from the Basel Area - Switzerland Global Enterprise (S-GE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNQXM0QWtTYUlVNVZNcW02aVZkbWEwNTY5Y0xRMklma25BUGtTMS1lVFJCczBZU1Z6UzN4dHVVMzgwcV9jbTNGUFhwTnB5a2c1Q0pGdkRxZkNWUUZPWDIyU01nR29hOHF1WnIzdnU4OEhZR2RyTzFQRk1oM3gxSlNBSXQ1Qnc?oc=5","date":"2023-03-08","type":"pipeline","source":"Switzerland Global Enterprise (S-GE)","summary":"Bachem receives order totaling more than 500 million Swiss francs - Switzerland Global Enterprise (S-GE)","headline":"Bachem receives order totaling more than 500 million Swiss francs - Switzerland Global Enterprise (S-GE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNR2w1MWo1M3RNZDRhWDBvTUptMTBjNFlCNEQxZWx0N2RfZHRZN18ybXo5Z1VMRTAwS0JvV0VZZ2hzdWt5cV9ZRFl4RzF4SEhlb3FOS0dmYjhEellDOG1aZ0lpQ2JDZDZZQTRXdHFPZlVvb2RCV19XVnp4R2lKRHRBb0RmV2FHeS1QcERCai1hbHEwRjBzQ2VLcmpud0pHdw?oc=5","date":"2020-12-10","type":"deal","source":"Fierce Biotech","summary":"Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race - Fierce Biotech","headline":"Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQeXJLN0pRTmY2Vklfd0g5bnIwQk1SdFYyb2E3U3BWUnhTZ2RBLTBiYnVfQ1NSdlMySFJyMUNLeFVsaWRrN29fSE5Uc21KQ3poRk5UeVZGOGFyRzl5MGhtaTRaWkwxZGZja25nM1NqcFBaZ25YOVdJcG9hR180UnF4bGVUYUpkclJkam40Unp1R0gwc0hZaUV0U0pidkZYMHNrZEtOTGtMZHExR0pNZjQtMDhoc0o?oc=5","date":"2020-12-10","type":"deal","source":"boehringer-ingelheim.com","summary":"Agreement-to-acquire-NBE-Therapeutics - boehringer-ingelheim.com","headline":"Agreement-to-acquire-NBE-Therapeutics - boehringer","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}